Heavy, long term exposure to marijuana may have biologically-based physical, mental, behavioral and social health consequences and may be "associated with diseases of the liver (particularly with co-existing hepatitis C), lungs, heart, and vasculature". It is recommended that cannabis use be stopped before and during pregnancy as it can result in negative outcomes for both the mother and baby. However, maternal use of marijuana during pregnancy does not appear to be associated with low birth weight or early delivery after controlling for tobacco use and other confounding factors. A 2014 review found that while cannabis use may be less harmful than alcohol use, the recommendation to substitute it for problematic drinking is premature without further study. Other side effects include cannabinoid hyperemesis syndrome.
The United Kingdom and Germany resumed commercial production in the 1990s. British production is mostly used as bedding for horses; other uses are under development. Companies in Canada, the UK, the United States, and Germany, among many others, process hemp seed into a growing range of food products and cosmetics; many traditional growing countries still continue to produce textile-grade fibre.
Researchers in New Zealand have studied whether cannabis can be used to treat severe motor and vocal tics in those suffering from Tourette syndrome. The study concluded that subjects who took a controlled THC-CBD medicated spray showed marked improvement in the frequency and severity of motor and vocal tics post-treatment. Although the study is only a small clinical trial, it is one of the first to specifically analyze the effects of cannabis on Tourette syndrome.
As with a fermented food like kombucha, slight natural variations are normal and to be expected in a product such as CBD oil because it is made from living plants. Changes in the weather, soil, and water can all impact the biology of the source material. While we verify Certificates of Analysis (and take many other criteria into consideration during our review process), even the most reputable five-star companies have no way to control for every variable in this organic process.
C.S. Lewis said “badness is only spoiled goodness.” This may be an apt quote regarding public perception. It’s true that hemp’s scientific name is the same as that other Cannabis sativa, marijuana, but its constituents are different. The three cannabis plants have three different species: Sativa, used for industrial fibers, oils, food, drugs and medicine; Indica, to induce sleep; and Ruderalis, for food production. Hemp seeds contain high amounts of essential fatty acids – more than any fish and most fish oil supplements. The oil has linoleic acid, alpha-linolenic acid, and at least 20 amino acids. Altogether, hemp supplies innumerable health benefits. After decades of misunderstanding, scientists have again been tapping the amazing potential of this versatile plant.
Karl W. Hillig, a graduate student in the laboratory of long-time Cannabis researcher Paul G. Mahlberg at Indiana University, conducted a systematic investigation of genetic, morphological, and chemotaxonomic variation among 157 Cannabis accessions of known geographic origin, including fiber, drug, and feral populations. In 2004, Hillig and Mahlberg published a chemotaxonomic analysis of cannabinoid variation in their Cannabis germplasm collection. They used gas chromatography to determine cannabinoid content and to infer allele frequencies of the gene that controls CBD and THC production within the studied populations, and concluded that the patterns of cannabinoid variation support recognition of C. sativa and C. indica as separate species, but not C. ruderalis. The authors assigned fiber/seed landraces and feral populations from Europe, Central Asia, and Turkey to C. sativa. Narrow-leaflet and wide-leaflet drug accessions, southern and eastern Asian hemp accessions, and feral Himalayan populations were assigned to C. indica. In 2005, Hillig published a genetic analysis of the same set of accessions (this paper was the first in the series, but was delayed in publication), and proposed a three-species classification, recognizing C. sativa, C. indica, and (tentatively) C. ruderalis. In his doctoral dissertation published the same year, Hillig stated that principal components analysis of phenotypic (morphological) traits failed to differentiate the putative species, but that canonical variates analysis resulted in a high degree of discrimination of the putative species and infraspecific taxa. Another paper in the series on chemotaxonomic variation in the terpenoid content of the essential oil of Cannabis revealed that several wide-leaflet drug strains in the collection had relatively high levels of certain sesquiterpene alcohols, including guaiol and isomers of eudesmol, that set them apart from the other putative taxa. Hillig concluded that the patterns of genetic, morphological, and chemotaxonomic variation support recognition of C. sativa and C. indica as separate species. He also concluded there is little support to treat C. ruderalis as a separate species from C. sativa at this time, but more research on wild and weedy populations is needed because they were underrepresented in their collection.
Soil characteristics, latitude and climatic stresses have been found to have significant effects on THC concentrations, and there are seasonal and even diurnal variations (Small 1979; Pate 1998b). However, the range of THC concentrations developed by low-THC cultivars (those typically with £0.3% THC) under different circumstances on the whole is limited, for the most part generally not varying more than 0.2 percentage points when grown in a range of circumstances, and usually less (note information in Scheifle et al. 1999; Scheifle 2000, Scheifle and Dragla 2000). Practically, this has meant in Canadian experience that a few cultivars have been eliminated from further commercial cultivation because they sometimes exceed the 0.3% level (‘Fedora 19’ and ‘Futura,’ authorized in 2000, have now been removed because some test results in several years exceeded 0.3%; ‘Finola’ and ‘Uniko B’ are under probation because of elevated levels), but on the whole most of the permitted cultivars have maintained highly consistent development of quite low levels of THC.
Did you get an answer for this? I have the exact same scenario. I'm treating my TN with Tegretol, and recently tried CBD. I think I took too much and there are some weird drug interactions with Tegretol and I felt quite stoned....was alone and talking to myself in my head thinking I was Einstein. It freaked me out a bit but I think I took too much. I'm trying lower doses again as recently my TN seems to be resisting the meds, although I have had a lot of emotional stress, which seems to be a trigger. Thanks!! Anna